Thursday, October 15, 2026

Silver Futures Went Down By Over 12% In The Last 21 Sessions

Silver Futures Went Down By Over 12% In The Last 21 Sessions

(VIANEWS) - Silver (SI) has been up by 12.1% for the last 21 sessions. At 05:51 EST on Wednesday, 7 August, Silver (SI) is $27.09.

Volume

Today's last reported volume for Silver is 17834, 99.99% below its average volume of 9083366492.88.

Volatility

Silver's last week, last month's, and last quarter's current intraday variation average was 1.24%, 0.75%, and 1.40%, respectively.

Silver's highest amplitude of average volatility was 1.24% (last week), 1.17% (last month), and 1.40% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Silver's commodity is considered to be oversold (<=20).

Previous days news about Silver (SI)

  • Silver price forecast: xag/usd faces bloodbath as fears of global slowdown intensify. According to FXStreet on Monday, 5 August, "The demand of the Silver as an metal with application in various industries, such as: Electric Vehicles, renewable energy, and wires and cables etc.", "Meanwhile, a sharp decline in US bond yields and the US Dollar (USD) due to growing speculation that the Federal Reserve (Fed) will deliver a bulk rate-cut in its September meeting fails to lift the Silver price. "
  • Silver price forecast: xag/usd remains tepid near $27.00 due to diminished safe-haven appeal. According to FXStreet on Tuesday, 6 August, "However, the downside of non-yielding metals like Silver could be restrained due to the expectation of a 50-basis point (bps) interest rate cut by the US Federal Reserve (Fed) in September. "
  • Silver price forecast: xag/usd declines below $27 as demand concerns escalate. According to FXStreet on Tuesday, 6 August, "Meanwhile, higher bond yields and a decent recovery in the US Dollar (USD) have also weighed on the Silver price. ", "The near-term outlook of the Silver price has become bearish as the 14-day Relative Strength Index (RSI) has shifted into the 20.00-60.00 range from the bullish range of 40.00-80.00. "

News about

  • According to FXStreet on Tuesday, 6 August, "This is expected to dent fuel demand and drags Crude Oil prices lower for the fourth straight day, which, in turn, is seen undermining demand for the commodity-linked Loonie. ", "Furthermore, the risk of a broader Middle East conflict continues to fuel concerns about supply disruptions from the key Oil producing region and could help limit losses for Crude Oil prices. "
  • According to FXStreet on Tuesday, 6 August, "Apart from this, subdued US Dollar (USD) price action, amid rising bets for a bigger interest rate cut by the Federal Reserve (Fed), turn out to be key factors acting as a tailwind for Crude Oil prices.", "In the absence of any relevant US economic releases on Tuesday, fresh geopolitical developments surrounding the ongoing conflicts in the Middle East will continue to influence Crude Oil prices. "
  • According to FXStreet on Monday, 5 August, "At the time of writing, Crude Oil (WTI) trades at $71.61 and Brent Crude at $75.42"

More news about Silver (SI).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com